drugset / Trial / NCT05297565
A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and tolerability of subcutaneous nivolumab vs intravenous nivolumab in participants with completely resected Stage IIIA/B/C/D or Stage IV melanoma.
Timeline
- Start
- 2022-08-02
- Primary completion
- 2024-02-08
- Completion
- 2024-02-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nivolumab | Monoclonal antibody | — | Subcutaneous |
| Comparator | Nivolumab | Monoclonal antibody | — | Intravenous |
| Background | rHuPH20 | Protein / enzyme biologic | — | — |